ResMed (RMD) Stock Forecast & Price Target

$272.66 +0.95 (+0.35%)

As of 03:35 PM Eastern

Compare

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Moderate Buy

Based on 16 Analyst Ratings

Sell
0

Hold
3

Buy
13

Based on 16 Wall Street analysts who have issued ratings for ResMed in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, 11 have given a buy rating, and 2 have given a strong buy rating for RMD.

Consensus Price Target

$292.00
7.09% Upside

According to the 16 analysts' twelve-month price targets for ResMed, the average price target is $292.00. The highest price target for RMD is $330.00, while the lowest price target for RMD is $270.00. The average price target represents a forecasted upside of 7.09% from the current price of $272.66.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for RMD and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for ResMed and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RMD Analyst Ratings Over Time

Type	Current Forecast 9/18/24 to 9/18/25	1 Month Ago 8/19/24 to 8/19/25	3 Months Ago 6/20/24 to 6/20/25	1 Year Ago 9/19/23 to 9/18/24
Strong Buy	2 Strong Buy rating(s)	2 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	11 Buy rating(s)	10 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	5 Hold rating(s)	5 Hold rating(s)
Sell	0 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$292.00	$274.83	$259.33	$202.45
Forecasted Upside	7.09% Upside	-3.84% Downside	2.24% Upside	-14.90% Downside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Hold

RMD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RMD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

ResMed Stock vs. The Competition

Type	ResMed	Medical Companies	S&P 500
Consensus Rating Score	2.94	2.78	2.53
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	6.81% Upside	13,666.66% Upside	10.84% Upside
News Sentiment Rating	Positive News See Recent RMD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/18/2025	Citigroup 2 of 5 stars	Laura Sutcliffe Not Rated	Initiated Coverage	Buy	$330.00	+21.36%
9/2/2025	CLSA 1 of 5 stars		Upgrade	Hold ➝ Outperform
8/1/2025	William Blair 2 of 5 stars		Upgrade	Strong-Buy
8/1/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Sutcliffe Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$285.00 ➝ $325.00	+16.25%
8/1/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Craig Wong-Pan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$294.00 ➝ $300.00	+7.31%
8/1/2025	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Block Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Hold	$240.00 ➝ $270.00	-3.42%
8/1/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$270.00 ➝ $290.00	+3.73%
8/1/2025	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brett Fishbin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$274.00 ➝ $298.00	+9.49%
8/1/2025	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Maeder Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$248.00 ➝ $270.00	-0.79%
5/20/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Bailey Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target	Overweight	$286.00	+16.50%
Get the Latest News and Ratings for RMD and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for ResMed and its competitors with MarketBeat's FREE daily newsletter.
4/24/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Low Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$286.00 ➝ $290.00	+22.49%
1/31/2025	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Matson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold
1/16/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Thillainathan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Buy
10/25/2024	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$280.00 ➝ $283.00	+18.39%
9/26/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Buy	$240.00 ➝ $270.00	+11.12%
9/24/2024	Baird R W Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Strong-Buy
9/18/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Peer Perform ➝ Underperform	$180.00	-28.25%
6/25/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
10/5/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target		$240.00 ➝ $165.00	+11.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:26 PM ET.

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

Here are some ways that investors could benefit from investing in ResMed Inc.:

ResMed Inc. recently reported strong quarterly earnings, exceeding analysts' expectations with earnings per share of $2.55, indicating robust financial health and operational efficiency.
The company has shown a significant year-over-year revenue growth of over 10%, reflecting its ability to expand its market presence and increase sales.
ResMed Inc. has increased its quarterly dividend to $0.60 per share, which represents a positive change from the previous dividend, signaling confidence in its ongoing profitability and commitment to returning value to shareholders.
The current stock price is around $279, which may be considered attractive for investors looking for growth in the medical equipment sector.
With a return on equity of over 25%, ResMed Inc. demonstrates effective management and a strong ability to generate profits from shareholders' investments.

ResMed
Bear Case

Investors should be bearish about investing in ResMed Inc. for these reasons:

Insider selling has been observed, with significant shares sold by both the Director and CEO, which may raise concerns about the company's future prospects and insider confidence.
The dividend payout ratio is approximately 25.24%, which, while sustainable, indicates that a significant portion of earnings is retained for reinvestment rather than distributed to shareholders.
Corporate insiders own only 0.71% of the company's stock, suggesting limited alignment between management and shareholder interests, which could impact decision-making.
Despite recent growth, the medical equipment market can be highly competitive and subject to regulatory changes, which may pose risks to future performance.
Market volatility can affect stock prices, and any downturn in the healthcare sector could negatively impact ResMed Inc.'s stock performance.

RMD Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for ResMed is $292.00, with a high forecast of $330.00 and a low forecast of $270.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 3 hold ratings, 11 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RMD shares.
: According to analysts, ResMed's stock has a predicted upside of 7.09% based on their 12-month stock forecasts.
: Over the previous 90 days, ResMed's stock had 3 upgrades by analysts.
: ResMed has been rated by research analysts at Citigroup, CLSA, KeyCorp, Mizuho, Piper Sandler, Royal Bank Of Canada, Stifel Nicolaus, UBS Group, and William Blair in the past 90 days.
: Analysts like ResMed more than other "medical" companies. The consensus rating score for ResMed is 2.94 while the average consensus rating score for "medical" companies is 2.78. Learn more on how RMD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:RMD) was last updated on 9/18/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ResMed (RMD) Stock Forecast & Price Target

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Consensus Price Target

RMD Analyst Ratings Over Time

RMD Analyst Recommendations By Month

RMD Price Targets by Month

ResMed Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy ResMed Stock? RMD Pros and Cons Explained

ResMed
Bull Case

ResMed
Bear Case

RMD Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ResMed (RMD) Stock Forecast & Price Target

ResMed - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Consensus Price Target

RMD Analyst Ratings Over Time

RMD Analyst Recommendations By Month

RMD Price Targets by Month

ResMed Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy ResMed Stock? RMD Pros and Cons Explained

ResMed Bull Case

ResMed Bear Case

RMD Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

ResMed
Bull Case

ResMed
Bear Case